<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712907</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-161202</org_study_id>
    <nct_id>NCT00712907</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow</brief_title>
  <official_title>Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High arterial blood oxygen tension leads to vasoconstriction of retinal vessels, possibly&#xD;
      related to an interaction between reactive oxygen species and endothelium-derived vasoactive&#xD;
      factors. Vitamin C is a potent antioxidant capable of reversing endothelial dysfunction due&#xD;
      to increased oxidant stress. Vitamin C appears to have vasodilatory properties, but the&#xD;
      underlying mechanisms are not well understood.&#xD;
&#xD;
      In the present study we hypothesized that hyperoxic vasoconstriction of retinal vessels could&#xD;
      be diminished by vitamin C.&#xD;
&#xD;
      Ocular blood flow will be determined by non-invasive methods, including laser Doppler&#xD;
      velocimetry and the Zeiss retinal vessel analyser.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal arterial and venous diameter (Zeiss retinal vessel analyzer)</measure>
    <time_frame>in total 6 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal blood flow velocity (laser Doppler velocimetry)</measure>
    <time_frame>in total 6 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure (applanation tonometry)</measure>
    <time_frame>in total 10 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ocular Physiology</condition>
  <condition>Regional Blood Flow</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin C (Mayrhofer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin C (Mayrhofer) 24mg/min i.v. for 64 min</intervention_name>
    <description>Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>100% O2 (AGA) two times for 12 min</intervention_name>
    <description>Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.&#xD;
Dosage reference: Strenn K 1997</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged between 19 and 35 years, nonsmokers&#xD;
&#xD;
          -  Body mass index between 15th and 85th percentile (Must A 1991)&#xD;
&#xD;
          -  Normal findings in the medical history and physical examination unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant&#xD;
&#xD;
          -  Normal laboratory values unless the investigator considers an abnormality to be&#xD;
             clinically irrelevant&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropia &lt; 3 Dpt.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical&#xD;
             trial in the 3 weeks preceding the study&#xD;
&#xD;
          -  Treatment in the previous 3 weeks with any drug&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  History of hypersensitivity to the trial drug or to drugs with a similar chemical&#xD;
             structure&#xD;
&#xD;
          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions&#xD;
             known to interfere with, distribution, metabolism or excretion of study drugs&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <last_update_submitted>July 9, 2008</last_update_submitted>
  <last_update_submitted_qc>July 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gabriele Fuchsj√§ger-Mayrl, MD</name_title>
    <organization>Department of Clinical Pharmacology</organization>
  </responsible_party>
  <keyword>vitamin C</keyword>
  <keyword>retinal blood flow</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>retinal vessel diameter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

